

Common drug interaction

What is drug interaction?

A drug interaction is a reaction between two (or more) drugs or between a drug and a food or beverage. A drug interaction can decrease or increase the action of a drug or cause unwanted side effects.

Interaction of some commonly use drug

| Drugs | Interaction | What should do? |
|---|---|--|
| Iron with PPI | Reduce iron absorption (iron needs acidic environment for absorption, PPI decrease acid secretion in stomach) | Avoid use concomitantly (if use concomitantly then give one in morning and other at night) |
| Azithromycin with ondansetron | Azithromycin together with ondansetron can increase the risk of an irregular heart rhythm | Avoid combine use |
| Clopidogrel with PPI | Decreased efficacy of clopidogrel | Avoid use of PPIs with clopidogrel, use aspirin or use prasugrel or use ranitidine with clopidogrel. |
| Beta-blockers with verapamil, diltiazem | Bradycardia, AV block | Avoid using together |
| Verapamil, diltiazem with digoxin | Increase digoxin levels, digoxin toxicity (mainly with verapamil) | Avoid use together, decrease digoxin dose by upto 50%, monitor digoxin levels |

| | | |
|--|---|---|
| Diuretics with digoxin | Increased digoxin toxicity due to hypokalemia | Use potassium sparing diuretic Monitor blood potassium levels |
| Sulfonylureas with fluconazole, H2-antagonists, clarithromycin, verapamil | Increased efficacy of sulfonylureas, hypoglycemia | Dose reduction of sulfonylurea, blood glucose monitoring |
| Sulfonylureas with rifampicin, phenytoin, carbamazepine, non-selective beta-blockers | Decreased efficacy of sulfonylureas, hyperglycemia | Increase dose of sulfonylurea, blood glucose monitoring |
| Metformin with Iodinated contrast media | High risk of contrast induced nephropathy | Contraindicated 48 hours prior and 48 hours after use of contrast media |
| DPP-4 inhibitors (vildagliptin, linagliptin) with Diltiazem, clarithromycin | Increased efficacy of DPP-4 inhibitors, hypoglycemia | Dose reduction of DPP-4 inhibitor, blood glucose monitoring |
| DPP-4 inhibitors (vildagliptin, linagliptin) with rifampicin | Decreased efficacy of DPP-4 inhibitors, hyperglycemia | Increase dose of DPP-4 inhibitor, blood glucose monitoring |

| | | |
|---|---|---|
| ACE inhibitors and ARBs | Increase potassium level | Avoid concomitant use |
| Carbamazepine plus cimetidine, erythromycin, clarithromycin or fluconazole | Increased carbamazepine levels | Monitor drug level, use other drugs |
| Phenytoin plus cimetidine, erythromycin, clarithromycin or fluconazole | Increased phenytoin levels | Monitor drug level, use other drugs |
| Theophylline and ciprofloxacin | Concurrent administration may lead to toxic increases in theophylline. This problem occurs because the hepatic metabolism of theophylline is inhibited by ciprofloxacin via the cytochrome P-450 enzyme system. | Avoid combine use |
| Warfarin plus aspirin | Increase bleeding, increase INR | Limit aspirin dosage to 100 mg per day and monitor INR. |
| Warfarin and NSAID | Increase the risk for gastrointestinal (GI) bleeding and the anticoagulant response of warfarin | Use paracetamol or other non-NSAID analgesic. |
| Warfarin plus ciprofloxacin, clarithromycin, erythromycin, metronidazole or trimethoprim-sulfamethoxazole | Increased effect of warfarin, generally within 1 week. | Select alternative antibiotic |
| Sildenafil and isosorbide mononitrate | Sildenafil may markedly increase the hypotensive effects of isosorbide | Before prescribe sildenafil must exclude IHD and co- |

| | | |
|--|--|---|
| | mononitrate | concomitant use of nitrates |
| Sildenafil plus cimetidine, erythromycin, itraconazole or ketoconazole | Increased sildenafil levels | Initiate sildenafil at 25-mg dose |
| Potassium chloride and spironolactone | The combination may result in hyperkalemia. The resulting hyperkalemia can be serious and may lead to sudden death. | Avoid using this two drugs concomitantly. |
| Clonidine and propranolol | This combination may produce a mysterious hypertension | Never use this combination |
| Methotrexate and probenecid | 2 to 3 fold increase in methotrexate levels. Probenecid acts as an active tubular secretion inhibitor and prevents methotrexate from being excreted, thus potentially causing toxicity. | Avoid combine use |
| Bromocriptine and pseudoephedrine | The interaction can lead to severe peripheral vasoconstriction, ventricular tachycardia, seizures, and possibly death. | Avoid combine use |
| Lithium plus NSAID or diuretic | Increased lithium levels | Decrease lithium dosage by 50% and monitor lithium levels |
| Oral contraceptive pills plus rifampicin | Decrease effectiveness of oral contraception | Avoid if possible. If combine therapy is necessary, have the patient take an oral |

| | | |
|---|---|---|
| | | contraceptive pill with a higher estrogen content (>35 µg of ethinyl estradiol) or recommend alternative method of contraception. |
| Carbamazepine with OCP | Decrease effectiveness of oral contraception | Avoid use together, use OCP with high dose oestrogen, use alternative method of contraception, use AEDs which do not interact with OCPs |
| HMG-CoA reductase inhibitor (statin) plus niacin, gemfibrozil, erythromycin or itraconazole | Possible rhabdomyolysis | Avoid if possible. If combine therapy is necessary, monitor the patient for toxicity |
| SSRI plus tricyclic antidepressant | Increased tricyclic antidepressant level | Monitor for anticholinergic excess and consider lower dosage of tricyclic antidepressant |
| SSRI plus selegiline or nonselective monoamine oxidase inhibitor | Hypertensive crisis, soon after initiation | Avoid combine use |
| SSRI plus tramadol | Increase potential for seizures; serotonin syndrome | Monitor the patient for signs and symptoms of serotonin syndrome. |